- Home
- LVTX vs PLUR Comparison
LVTX vs PLUR Comparison
Compare LVTX & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- PLUR
- Stock Information
- Founded
- LVTX 2016
- PLUR 2001
- Country
- LVTX Netherlands
- PLUR Israel
- Employees
- LVTX N/A
- PLUR N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LVTX Health Care
- PLUR Health Care
- Exchange
- LVTX Nasdaq
- PLUR Nasdaq
- Market Cap
- LVTX 40.0M
- PLUR 36.9M
- IPO Year
- LVTX 2021
- PLUR N/A
- Fundamental
- Price
- LVTX $1.62
- PLUR $3.69
- Analyst Decision
- LVTX Hold
- PLUR Strong Buy
- Analyst Count
- LVTX 4
- PLUR 1
- Target Price
- LVTX $1.58
- PLUR $12.00
- AVG Volume (30 Days)
- LVTX 485.2K
- PLUR 9.2K
- Earning Date
- LVTX 12-09-2025
- PLUR 11-11-2025
- Dividend Yield
- LVTX N/A
- PLUR N/A
- EPS Growth
- LVTX N/A
- PLUR N/A
- EPS
- LVTX N/A
- PLUR N/A
- Revenue
- LVTX $4,990,000.00
- PLUR $1,336,000.00
- Revenue This Year
- LVTX N/A
- PLUR $97.38
- Revenue Next Year
- LVTX N/A
- PLUR $293.97
- P/E Ratio
- LVTX N/A
- PLUR N/A
- Revenue Growth
- LVTX N/A
- PLUR 309.82
- 52 Week Low
- LVTX $0.85
- PLUR $3.33
- 52 Week High
- LVTX $2.00
- PLUR $7.13
- Technical
- Relative Strength Index (RSI)
- LVTX 61.51
- PLUR 37.09
- Support Level
- LVTX $1.58
- PLUR $3.60
- Resistance Level
- LVTX $1.63
- PLUR $4.00
- Average True Range (ATR)
- LVTX 0.06
- PLUR 0.18
- MACD
- LVTX 0.01
- PLUR -0.02
- Stochastic Oscillator
- LVTX 99.06
- PLUR 9.68
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.